和邦生物
(603077)
| 流通市值：223.44亿 | | | 总市值：223.44亿 |
| 流通股本：88.32亿 | | | 总股本：88.32亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,888,094,804.07 | 1,387,806,236.79 | 7,187,510,832.55 | 5,926,520,025.82 |
| 营业收入 | 2,888,094,804.07 | 1,387,806,236.79 | 7,187,510,832.55 | 5,926,520,025.82 |
| 二、营业总成本 | 2,396,219,339.8 | 1,212,017,795.36 | 7,030,846,930.02 | 5,726,755,746.57 |
| 营业成本 | 2,054,314,877.22 | 1,049,666,002.59 | 6,359,490,472.79 | 5,260,558,534.55 |
| 税金及附加 | 31,495,952.19 | 10,945,904.68 | 70,739,812.31 | 51,463,992.97 |
| 销售费用 | 48,130,003.16 | 22,890,987.23 | 91,289,716.57 | 64,041,100.06 |
| 管理费用 | 190,502,080.93 | 93,884,258.46 | 407,807,069.9 | 289,279,526.44 |
| 研发费用 | 8,218,272.94 | 3,997,047.23 | 17,313,627.52 | 12,370,674.89 |
| 财务费用 | 63,558,153.36 | 30,633,595.17 | 84,206,230.93 | 49,041,917.66 |
| 其中:利息费用 | 56,650,002.16 | 28,690,179.85 | 125,386,654.84 | 86,395,013.74 |
| 其中:利息收入 | 29,313,838.25 | 15,120,114.11 | 58,799,215.46 | 41,079,771.87 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 6,847,995.08 | -1,707,295.39 | -5,005,111.27 | -4,217,703.42 |
| 资产处置收益 | 7,434.41 | - | -4,361,435.6 | 1,237,084.79 |
| 资产减值损失(新) | -39,700,767.03 | 43,706,713.06 | -763,172,731.83 | -14,319,120.94 |
| 信用减值损失(新) | -12,184,606.75 | -14,055,590.17 | -12,106,950.27 | -22,193,435.84 |
| 其他收益 | 4,141,605.09 | 1,631,999.7 | 25,120,191.57 | 24,537,991.6 |
| 四、营业利润 | 450,987,125.07 | 205,364,268.63 | -602,862,134.87 | 184,809,095.44 |
| 加:营业外收入 | 214,799.98 | 178,109.69 | 811,995.35 | 60,192.18 |
| 减:营业外支出 | 632,173 | 478,128.38 | 28,792,265.62 | 14,447,846.07 |
| 五、利润总额 | 450,569,752.05 | 205,064,249.94 | -630,842,405.14 | 170,421,441.55 |
| 减:所得税费用 | 75,987,787.47 | 32,779,633.14 | 81,822,226.37 | 93,978,527.11 |
| 六、净利润 | 374,581,964.58 | 172,284,616.8 | -712,664,631.51 | 76,442,914.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 374,581,964.58 | 172,284,616.8 | -712,664,631.51 | 76,442,914.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 380,158,275.34 | 173,589,052.64 | -536,406,669.49 | 93,108,537.81 |
| 少数股东损益 | -5,576,310.76 | -1,304,435.84 | -176,257,962.02 | -16,665,623.37 |
| 扣除非经常损益后的净利润 | 375,054,683.83 | 171,310,111.83 | -526,321,542.31 | 89,690,946.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.02 | -0.07 | 0.01 |
| (二)稀释每股收益 | 0.04 | 0.02 | -0.05 | 0.01 |
| 八、其他综合收益 | -35,768,548.06 | -20,318,866.56 | -28,120,800.15 | -18,262,832.26 |
| 归属于母公司股东的其他综合收益 | -33,521,422.06 | -19,094,907.6 | -26,284,027.47 | -18,651,953.83 |
| 九、综合收益总额 | 338,813,416.52 | 151,965,750.24 | -740,785,431.66 | 58,180,082.18 |
| 归属于母公司股东的综合收益总额 | 346,636,853.28 | 154,494,145.04 | -562,690,696.96 | 74,456,583.98 |
| 归属于少数股东的综合收益总额 | -7,823,436.76 | -2,528,394.8 | -178,094,734.7 | -16,276,501.8 |
| 公告日期 | 2026-08-18 | 2026-04-21 | 2026-04-21 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |